Correction of hyponatremia

Seminars in Nephrology

Volumn 21, Issue 3, 2001, Pages 269-272

  Gross, Peter ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

LIXIVAPTAN; MOZAVAPTAN; VASOPRESSIN; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V2 RECEPTOR;

CONFERENCE PAPER; DRUG EFFICACY; HEART FAILURE; HUMAN; HYPONATREMIA; INAPPROPRIATE VASOPRESSIN SECRETION; KIDNEY CONCENTRATING CAPACITY; LIVER CIRRHOSIS; NONHUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; VASOPRESSIN RELEASE; WATER DEPRIVATION;

EID: 0035034634     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1053/snep.2001.21655     Document Type: Conference Paper

References (25)

1. Severe hyponatremia in hospital inpatients
2. Role of vasopressin in brain damage from hyponatremic encephalopathy
3. Advanced heart failure: The possible role of endothelin in kidney failure; baroreceptor mechanism of vasopressin stimulation in advanced heart failure and hyponatremia
4. Cloning of the human type-2-vasopressin receptor gene
5. Beneficial effects of V2-vasopressin antagonist (ANTAG) in the hyponatremia of clinical cardiac failure (CHF), SIADH and liver cirrhosis (CI)
6. Characterization of SR 121463A, a highly potent selective, orally active vasopressin V2-receptor antagonist
7. Upregulation of aquaporin-2 water channel expression in congestive heart failure rat
8. Effect of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs
9. Effect of long-term treatment with selective vasopressin V1 and V2 receptor antagonist on the development of heart failure in rats
10. Enhancement of vascular action of arginine vasopressin by diminishing extracellular sodium concentration
11. Role of diuretics, hormonal derangements, and clinical setting of hyponatremia in medical patients
12. Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis and pregnancy
13. Therapeutic efficacy of the non-peptide AVP antagonist OPC-31260 in cirrhotic rats
14. In vivo diuretic effect of a new non-peptide arginine vasopressin antagonist, OPC-31260, in conscious rats
15. Therapeutic and diagnostic potential of a vasopressin-2 antagonist for impaired water handling in cirrhosis
16. The treatment of severe hyponatremia
17. Neurogenic disorders of osmoregulation
18. Therapeutic efficacy of non-peptide ADH antagonist OPC-31260 in SIADH rats
19. Role of water channel AQP-CD in water retention in SIADH and cirrhotic rats
20. Acute aquaresis by the nonpeptide arginine vasopressin (AVP) antagonist OPC-31260 improves hyponatremia in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH)
21. Aquaretic effects of the nonpeptide V2 antagonist OPC-31260 in hydropenic humans
22. V2 receptor antagonism of dDAVP-induced release of hemostasis factors in conscious dogs